Publication

Article

BioPharm International

BioPharm International-12-16-2013
Volume2013 eBook
Issue 1

Creating Better Medicines through Better Conjugation

Author(s):

Cynthia A. Challener

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.

 

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.

Read this article

from BioPharm International’s 2013 Innovation Updates and Strategies eBook.

 

 

 

 

 

 

 

Articles in this issue
BPsupp1213_AmbrexProfile_200.jpg
Creating Better Medicines through Better Conjugation
BPsupp1213_Patent_200.jpg
Recovering Patent Life with Patent Term Extension
BPsupp1213_Vetter_200.jpg
Strategic Outsourcing in Clinical Development
BPsupp1213_NPSPharma_200.jpg
Leveraging Development Strengths Drives Therapies to Market
BPsupp1213_Kalypso_200.jpg
Driving Innovation in Biopharmaceuticals
BPsupp1213_Crowdfunding_200.jpg
Crowdfunding Biopharmaceutical Innovation

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com
August 8th 2025

Next for Biopharma: Speed, Strategy, and Smarter Systems

Mike Hennessy Jr.
Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?
August 8th 2025

Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?

Feliza Mirasol
B-cell, white blood cell 3D, type of lymphocyte interacting with a virus. Adaptive immune response, CAR-T cell therapy. B cell is humoral immunity component of the immune system producing antibodies | Image Credit: © Corona Borealis - stock.adobe.com
August 8th 2025

NanoCell’s LNP Platform Shows Promise for In-Vivo CAR-T Development

Patrick Lavery
Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically
August 8th 2025

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Felicity Thomas
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 8th 2025

Lilly’s AD Therapy, Kisunla, Shows Increasing Benefit in Treatment of Early AD

Feliza Mirasol
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 8th 2025

Roche Divulges New Alzheimer’s Disease Research Data at AAIC 2025

Feliza Mirasol
© 2025 MJH Life Sciences

All rights reserved.